MARKET

RXRX

RXRX

Recursion Pharmaceuticals, Inc.
NASDAQ
3.350
+0.060
+1.82%
Pre Market: 3.350 0 0.00% 07:56 08/12 EDT
OPEN
3.320
PREV CLOSE
3.290
HIGH
3.420
LOW
3.270
VOLUME
38.58K
TURNOVER
--
52 WEEK HIGH
7.18
52 WEEK LOW
2.770
MARKET CAP
1.79B
P/E (TTM)
-3.2267
1D
5D
1M
3M
1Y
5Y
1D
Short interest heatmap: Here are the most heavily bet-against stocks
Seeking Alpha · 22h ago
Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News
Seeking Alpha · 1d ago
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analysts Just Trimmed Their Revenue Forecasts By 19%
Simply Wall St · 2d ago
Weekly Report: what happened at RXRX last week (0803-0807)?
Weekly Report · 2d ago
Recursion Pharmaceuticals (RXRX) Is Up 7.3% After Mixed Q2 Results With Narrower Net Loss
Simply Wall St · 3d ago
Recursion Pharmaceuticals (RXRX) Reported Q2 Revenue Pressure, Is The Valuation Gap Too Wide?
Simply Wall St · 4d ago
TD Cowen Keeps Their Hold Rating on Recursion Pharmaceuticals (RXRX)
TipRanks · 6d ago
Recursion Pharmaceuticals (RXRX) Stock Sinks As Cash Burn Dominates AI Drug Story
Simply Wall St · 6d ago
More
About RXRX
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.

Webull offers Recursion Pharmaceuticals Inc stock information, including NASDAQ: RXRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RXRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RXRX stock methods without spending real money on the virtual paper trading platform.